Phase I/II clinical trial of regorafenib plus durvalumab (MEDI4736) in patients with chemotherapy-refractory advanced biliary tract cancers.
| Autor: | Al-Rajabi, Raed Moh'd Taiseer, Kasi, Anup, Baranda, Joaquina Celebre, Saeed, Anwaar, Li, Haoran, Bruey, Collin, Best, Shaun, Phadnis, Milind A., Sun, Weijing |
|---|---|
| Zdroj: | Journal of Clinical Oncology; 2024 Supplement 3, Vol. 42, pTPS581-TPS581, 151p |
| Databáze: | Supplemental Index |
| Externí odkaz: |
|